Patent, IP, Tech Transactions & FDA Regulatory FAQs
Answers from Our Patent Attorneys, Patent Agents & FDA Regulatory Advisors
These answers are written by our attorneys and patent agents for the people who make intellectual property decisions: founders, executives, in-house counsel, investors and inventors. Each answer states the rule, cites the statute, regulation or agency guidance behind it, and says what to do next. They are general information, not legal advice.
International IP Strategy
- What Is a Patent?
- What is “Patentable”?
- What Is Novelty in Patent Law?
- What is "Obviousness"?
- What Is Enablement?
-
More International IP Strategy
- What Is the Written Description Requirement, and How Do I Satisfy It?
- How to Enable an LLM Workflow Patent Application
- Do Patents Create Monopolies?
- What Is the Anatomy of a Patent?
- How Do U.S. and Foreign Patent Laws Differ?
- What Does the Paris Convention Priority Year Protect?
- What Is the U.S. Patent Prosecution Timeline After National Phase Entry?
- What Is Track One Prioritized Examination?
- What Are Intangible Assets?
- What Determines the Strength of a Trade Secret?
- How Are Trade Secrets Enforced?
- How Do Trade Secrets Compare to Patents?
